Price Alert

Immunome Inc. (IMNM)

NASDAQ: IMNM · Real-Time Price · USD

9.95

0.01 (0.10%)

At close: Aug 15, 2025, 9:55 AM

0.10% (1D)

Bid	9.95
Market Cap	866.1M
Revenue (ttm)	10.94M
Net Income (ttm)	-205.11M
EPS (ttm)	-3.05
PE Ratio (ttm)	-3.26
Forward PE	-4.1
Analyst	Buy

Ask	10.07
Volume	56,775
Avg. Volume (20D)	910,629
Open	9.95
Previous Close	9.94
Day's Range	9.92 - 10.06
52-Week Range	5.15 - 16.73
Beta	1.93

About IMNM

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol IMNM

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for IMNM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Immunome has released their quartely earnings on Aug 6, 2025:

Revenue of $4.01M exceeds estimates by $2.41M, with 69.84% YoY growth.

EPS of -0.5 exceeds estimates by 0.01, with 16.67% YoY growth.

Next Earnings Release

Immunome Inc. is scheduled to release its earnings on Nov 12, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

4 months ago

+7.19%

Immunome shares are trading higher after Lake Stre... Unlock content with Pro Subscription

6 months ago

+1.19%

Immunome shares are trading lower after the company announced a $125 million proposed public offering.

News

3 days ago · seekingalpha.com

Immunome: SpringWorks Buyout Informs The Potential Upside Here

Immunome's lead asset, varegacestat, shows promising efficacy in desmoid tumors, with phase 3 topline data expected by the end of 2025. IMNM holds Orphan Drug designations in the US and Europe, potent...

1 week ago · zacks.com

Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates

Immunome, Inc. (IMNM) came out with a quarterly loss of $0.5 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to a loss of $0.49 per share a year ago.

1 week ago · fool.com

Immunome (IMNM) Q2 Revenue Surges 382%

Immunome (IMNM -3.59%), a clinical-stage biotechnology company developing targeted therapies for cancer, reported its second quarter 2025 earnings on August 6, 2025. The standout news was a substantia...

1 week ago · businesswire.com

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced toda...

1 month ago · zacks.com

Immunome (IMNM) Soars 6.0%: Is Further Upside Left in the Stock?

Immunome (IMNM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength d...

2 months ago · zacks.com

Immunome (IMNM) Upgraded to Buy: Here's What You Should Know

Immunome (IMNM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · zacks.com

Wall Street Analysts See a 158.17% Upside in Immunome (IMNM): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 158.2% in Immunome (IMNM). While the effectiveness of this highly sought-after metric is questionable, the posi...

2 months ago · zacks.com

Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 188.6% in Immunome (IMNM). While the effectiveness of this highly sought-after metric is questionable, the posi...

2 months ago · businesswire.com

Immunome to Present at Upcoming Investor Conferences

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome to Present at Upcoming Investor Conferences.